Altman Advisors Inc. Boosts Holdings in Novartis AG (NYSE:NVS)

Altman Advisors Inc. raised its position in shares of Novartis AG (NYSE:NVSFree Report) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,934 shares of the company’s stock after purchasing an additional 217 shares during the quarter. Altman Advisors Inc.’s holdings in Novartis were worth $1,508,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Operose Advisors LLC bought a new position in Novartis during the third quarter valued at $28,000. Planned Solutions Inc. acquired a new stake in Novartis during the fourth quarter worth about $31,000. AdvisorNet Financial Inc increased its holdings in Novartis by 480.0% in the fourth quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock valued at $35,000 after buying an additional 288 shares in the last quarter. Nordwand Advisors LLC purchased a new stake in shares of Novartis during the fourth quarter worth about $39,000. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in Novartis in the 3rd quarter valued at $39,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NVS. BMO Capital Markets raised their price objective on Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 24th. Morgan Stanley began coverage on Novartis in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price target on the stock.

Get Our Latest Report on Novartis

Novartis Stock Down 0.1 %

NVS traded down $0.09 on Wednesday, reaching $103.22. The company’s stock had a trading volume of 1,058,321 shares, compared to its average volume of 1,542,449. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.90 and a quick ratio of 0.71. The business’s 50 day moving average is $97.12 and its 200 day moving average is $99.31. Novartis AG has a 1 year low of $92.19 and a 1 year high of $108.78. The stock has a market cap of $210.98 billion, a price-to-earnings ratio of 13.93, a price-to-earnings-growth ratio of 1.63 and a beta of 0.53.

Novartis (NYSE:NVSGet Free Report) last posted its earnings results on Tuesday, April 23rd. The company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.73 by $0.07. The firm had revenue of $11.83 billion for the quarter, compared to analysts’ expectations of $11.50 billion. Novartis had a return on equity of 32.15% and a net margin of 31.33%. As a group, research analysts forecast that Novartis AG will post 7.27 EPS for the current fiscal year.

Novartis Increases Dividend

The business also recently declared an annual dividend, which was paid on Thursday, March 7th. Stockholders of record on Friday, March 8th were paid a dividend of $3.7772 per share. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend was Thursday, March 7th. This is an increase from Novartis’s previous annual dividend of $3.47. Novartis’s dividend payout ratio is 32.79%.

Novartis Company Profile

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Further Reading

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with's FREE daily email newsletter.